
Please try another search
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of solid tumors and induction of cancer specific antibodies. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Jaekyung Kim | 60 | - | CEO & Chairman of the Board |
Wan Ki Hong | 66 | - | Independent Outside Director |
Youngwoo Lee | 67 | - | Auditor |
YongJae Jang | 58 | - | Independent Outside Director |
JaeSik Seo | 49 | - | Independent Outside Director |
ByeongUk Jeong | 59 | - | Independent Outside Director |
SangGeun Park | 49 | - | Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review